These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20676947)

  • 81. Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin.
    Pearton M; Kang SM; Song JM; Kim YC; Quan FS; Anstey A; Ivory M; Prausnitz MR; Compans RW; Birchall JC
    Vaccine; 2010 Aug; 28(37):6104-13. PubMed ID: 20685601
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
    Ross TM; Mahmood K; Crevar CJ; Schneider-Ohrum K; Heaton PM; Bright RA
    PLoS One; 2009 Jun; 4(6):e6032. PubMed ID: 19554101
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Vaccination with influenza hemagglutinin-loaded ceramic nanoporous microneedle arrays induces protective immune responses.
    Schepens B; Vos PJ; Saelens X; van der Maaden K
    Eur J Pharm Biopharm; 2019 Mar; 136():259-266. PubMed ID: 30731115
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses.
    Liu J; Ren Z; Wang H; Zhao Y; Wilker PR; Yu Z; Sun W; Wang T; Feng N; Li Y; Wang H; Ji X; Li N; Yang S; He H; Qin C; Gao Y; Xia X
    Int Immunopharmacol; 2018 Oct; 63():119-128. PubMed ID: 30081250
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.
    Low JG; Lee LS; Ooi EE; Ethirajulu K; Yeo P; Matter A; Connolly JE; Skibinski DA; Saudan P; Bachmann M; Hanson BJ; Lu Q; Maurer-Stroh S; Lim S; Novotny-Diermayr V
    Vaccine; 2014 Sep; 32(39):5041-8. PubMed ID: 25045806
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
    Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
    Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
    Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
    Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
    Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope.
    Chen S; Zheng D; Li C; Zhang W; Xu W; Liu X; Fang F; Chen Z
    Biomed Res Int; 2015; 2015():901817. PubMed ID: 25767809
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.
    Morçӧl T; Hurst BL; Tarbet EB
    Vaccine; 2017 Aug; 35(35 Pt B):4569-4577. PubMed ID: 28716554
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.
    Venereo-Sanchez A; Gilbert R; Simoneau M; Caron A; Chahal P; Chen W; Ansorge S; Li X; Henry O; Kamen A
    Vaccine; 2016 Jun; 34(29):3371-80. PubMed ID: 27155499
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Immune Correlates of Protection Induced by Virus-Like Particles Containing 2009 H1N1 Pandemic Influenza HA, NA or M1 Proteins.
    Moon EK; Kang HJ; Chu KB; Lee SH; Lee DH; Soh Y; Quan FS
    Immunol Invest; 2019 May; 48(4):355-366. PubMed ID: 30430891
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles.
    Stinson JA; Boopathy AV; Cieslewicz BM; Zhang Y; Hartman NW; Miller DP; Dirckx M; Hurst BL; Tarbet EB; Kluge JA; Kosuda KM
    Vaccine; 2021 Sep; 39(38):5410-5421. PubMed ID: 34391593
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Microneedles enable the development of skin-targeted vaccines against coronaviruses and influenza viruses.
    Nguyen TT; Nguyen TTD; Tran NM; Nguyen HT; Vo GV
    Pharm Dev Technol; 2022 Jan; 27(1):83-94. PubMed ID: 34802372
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Development of vaccine formulations: past, present, and future.
    D'Amico C; Fontana F; Cheng R; Santos HA
    Drug Deliv Transl Res; 2021 Apr; 11(2):353-372. PubMed ID: 33598818
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Separable arrowhead microneedles.
    Chu LY; Prausnitz MR
    J Control Release; 2011 Feb; 149(3):242-9. PubMed ID: 21047538
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Microneedles: An Emerging Vaccine Delivery Tool and a Prospective Solution to the Challenges of SARS-CoV-2 Mass Vaccination.
    Feng YX; Hu H; Wong YY; Yao X; He ML
    Pharmaceutics; 2023 Apr; 15(5):. PubMed ID: 37242591
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Virus-Like Particle: Evolving Meanings in Different Disciplines.
    Hyman P; Trubl G; Abedon ST
    Phage (New Rochelle); 2021 Mar; 2(1):11-15. PubMed ID: 36148434
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Microneedle-Based Natural Polysaccharide for Drug Delivery Systems (DDS): Progress and Challenges.
    Damiri F; Kommineni N; Ebhodaghe SO; Bulusu R; Jyothi VGSS; Sayed AA; Awaji AA; Germoush MO; Al-Malky HS; Nasrullah MZ; Rahman MH; Abdel-Daim MM; Berrada M
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.